Cigdem Selli

Marie Skłodowska-Curie Fellow

  • Cancer Research UK Edinburgh Centre
  • Institute of Genetics and Molecular Medicine

Contact details



Applied Bioinformatics of Cancer
University of Edinburgh Cancer Research Centre, IGMM
Crewe Road South

Post code


Cigdem Selli is a Marie Skłodowska-Curie Research Fellow in Applied Bioinformatics of Cancer group where she investigates long-term letrozole-therapy-induced transcriptomic and proteomic changes in oestrogen receptor-positive (ER+) breast cancer. Cigdem also contributes to day-to-day supervision of MSc dissertation, and PhD rotation students, and public science engagement.


2013-3 months, Visiting Postdoctoral Researcher (EMBO fellow), Edinburgh Cancer Research Centre, The University of Edinburgh, UK

2006-2011, PhD in Pharmacology, Ege University, Institute of Health Sciences, Turkey

2002-2005, MSc in Pharmacology, Ege University, Institute of Health Sciences, Turkey

1998-2002, B.S. in Pharmacy, Ege University, Faculty of Pharmacy, Turkey

Responsibilities & affiliations

2017-,  Full Member, British Association for Cancer Research (BACR), UK

2017-,  Associate Member, Society of Spanish Researchers in the UK (SRUK/CERU), UK

2016-,  Member, Marie Curie Alumni Association,  European Union 

2014-, Member, Education and Science Workers' Union (Egitim-Sen), Turkey

2014-, Volunteer, TEMA Turkish Foundation for Combating Soil Erosion, for Reforestation and The Protection of Natural Habitats

2013-, Member, Contemporary Pharmacists' Association, Turkey

2006- ,  Member,  The Biochemical Society, UK

2005-,  Member, Turkish Pharmacological Society

2002-, Member, Turkish Pharmacists' Association

2002-, Member, Turkish Red Crescent

Open to PhD supervision enquiries?


Current research interests

My current research is focused on the investigation of tumour dormancy in breast cancer using bioinformatics analysis of high-throughput transcriptomic and proteomic data to identify predictive molecular signatures for individualized treatment of breast cancer. We aim to characterize molecular profiles of dormant cells using a clinical model of breast cancer dormancy. This work has the potential to cure more women of their breast cancer by identification of potential classes of treatments that may overcome breast cancer treatment resistance and decrease treatment costs by individualized treatment of breast cancer.

Past research interests

My previous studies are focused on the role of transient receptor potential canonical (TRPC) ion channels and calcium signalling in age-related arterial changes and hepatocellular carcinogenesis.

Affiliated research centres

  • Ege University, Faculty of Pharmacy, Department of Pharmacology

Current project grants

Wellcome Trust – The University of Edinburgh, Institutional Strategic Support Fund (ISSF3), Co-primary investigator
Marie Skłodowska-Curie Individual Fellowship (EU H2020-MSCA-IF, 658170), Co-primary investigator

Invited speaker

Selected oral presentation, UK Breast Cancer Research Symposium, London, 22-23 July. 

Selli C, Turnbull AK, Renshaw L, Thomas JS, Dixon JM, Sims AH. “Long-term neoadjuvant treatment as a clinical model of breast cancer dormancy”


14/09/2014 –15/09/2014 Organizing Committee Member, "Ion Channels and Calcium Signalling Workshop”, Faculty of Pharmacy, Ege University, Turkey.

30/05/2014 –31/05/2014 Lecturer, “New Pharmacological Targets: Potential Role of microRNAs in Diagnosis and Treatment”, Turkish Pharmacological Society 21th Postgraduate Education Symposium, Faculty of Pharmacy, Ege University, Turkey.

24/06/2010 –27/06/2010 Organizing Committee Member, “International Postgraduate Student Meeting on Pharmaceutical Sciences, IPSMPS”, the number of participant >100, Faculty of Pharmacy, Ege University, Turkey.